Details for Patent: 11,690,845
✉ Email this page to a colleague
Which drugs does patent 11,690,845 protect, and when does it expire?
Patent 11,690,845 protects ORIAHNN (COPACKAGED) and ORILISSA and is included in two NDAs.
This patent has nine patent family members in nine countries.
Summary for Patent: 11,690,845
| Title: | Methods of administering elagolix |
| Abstract: | The present disclosure relates to the use of GnRH receptor antagonists for the treatment of endometriosis, uterine fibroids, polycystic ovary syndrome (PCOS), or adenomyosis. In particular, the present disclosure describes methods for treating such gynecological disorders, where the methods involve administration of elagolix and may further involve co-administration of a CYP2B6 substrate (e.g., bupropion) or a CYP2C19 substrate (e.g., omeprazole). |
| Inventor(s): | Farah N. Ali, Nael M. Mostafa, Ahmed Nader, Mohamad Shebley |
| Assignee: | AbbVie Inc |
| Application Number: | US17/004,817 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 11,690,845 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 11,690,845
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | ORIAHNN (COPACKAGED) | elagolix sodium,estradiol,norethindrone acetate; elagolix sodium | CAPSULE;ORAL | 213388-001 | May 29, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS) USING 300 MG ELAGOLIX WHILE CO-ADMINISTERING OMEPRAZOLE | ⤷ Start Trial | ||||
| Abbvie | ORILISSA | elagolix sodium | TABLET;ORAL | 210450-001 | Jul 23, 2018 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS USING 150 MG OR 200 MG ELAGOLIX WHILE CO-ADMINISTERING OMEPRAZOLE | ⤷ Start Trial | ||||
| Abbvie | ORILISSA | elagolix sodium | TABLET;ORAL | 210450-002 | Jul 23, 2018 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS USING 150 MG OR 200 MG ELAGOLIX WHILE CO-ADMINISTERING OMEPRAZOLE | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,690,845
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2020433822 | ⤷ Start Trial | |||
| Brazil | 112022017681 | ⤷ Start Trial | |||
| Canada | 3174571 | ⤷ Start Trial | |||
| China | 115515592 | ⤷ Start Trial | |||
| European Patent Office | 4114396 | ⤷ Start Trial | |||
| Israel | 296196 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
